Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo.
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
The metabolism of glucagon-like peptide-1 (GLP-1) has not been studied in detail, but it is known to be rapidly cleared from the circulation. Measurement by RIA is hampered by the fact that most antisera are side-viewing or C-terminally directed, and recognize both intact GLP-1 and biologically inactive. N-terminally truncated fragments. Using high pressure liquid chromatography in combination with RIAs, methodology allowing specific determination of both intact GLP-1 and its metabolites was developed. Human plasma was shown to degrade GLP-1-(7-36)amide, forming an N-terminally truncated peptide with a t1/2 of 20.4 +/- 1.4 min at 37 C (n = 6). This was unaffected by EDTA or aprotinin. Inhibitors of dipeptidyl peptidase-IV or low temperature (4 C) completely prevented formation of the metabolite, which was confirmed to be GLP-1-(9-36)amide by mass spectrometry and sequence analysis. High pressure liquid chromatography revealed the concentration of GLP-1-(9-36)amide to be 53.5 +/- 13.7% of the concentration of endogenous intact GLP-1 in the fasted state, which increased to 130.8 +/- 10.0% (P < 0.01; n = 6) 1 h postprandially. Metabolism at the C-terminus was not observed. This study suggests that dipeptidyl peptidase-IV is the primary mechanism for GLP-1 degradation in human plasma in vitro and may have a role in inactivating the peptide in vivo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GIP and GLP-1 are both degraded very quickly by dipeptidyl peptidase 4 (DPP4) [57–59], making analogues of these endogenous hormones poor drug candidates.”
From Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes (2024) · cites this paper as [57]
Citations
Cites
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316798 · Cited by 670
Self-citationØRSKOV, C., HOLST, J. J., & NIELSEN, O. V. (1988) · Endocrinology · doi:10.1210/endo-123-4-2009 · Cited by 396
Self-citationOrskov, C., Jeppesen, J., Madsbad, S., & Holst, J. J. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115012 · Cited by 378
Self-citationØrskov, C., Wettergren, A., & Holst, J. J. (1993) · Diabetes · doi:10.2337/diab.42.5.658 · Cited by 325
Self-citationGlucagon-like peptide-1, a new hormone of the entero-insular axis
Ørskov, C. (1992) · Diabetologia · doi:10.1007/bf00429088 · Cited by 293
Structure-activity studies of glucagon-like peptide-1.
Adelhorst, K., Hedegaard, B. B., Knudsen, L. B., & Kirk, O. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37366-0 · Cited by 282
New developments in the incretin concept
Creutzfeldt, W., & Ebert, R. (1985) · Diabetologia · doi:10.1007/bf00281990 · Cited by 279
Dipeptidyl peptidase IV, a kidney brush-border serine peptidase
Kenny, A. J., Booth, A. G., George, S. G., Ingram, J., Kershaw, D., Wood, E. J., & Young, A. R. (1976) · Biochemical Journal · doi:10.1042/bj1570169 · Cited by 254
Cited by
Items 601–700 of 798
Péptido similar al glucagón tipo 1 y supervivencia de la célula cardiaca
Ravassa, S., Zudaire, A., & Díez, J. (2012) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2012.07.007 · Cited by 13
“PKA cAMP Decreased inflammation Myocardial arteries GLP-1 (9-36) D P P -I V”
BackgroundPathophysiology and treatment of patients with type 2 diabetes exhibiting failure to oral drugs
Efendić, S., Alvarsson, M., Brismar, K., & Wagner, H. (2007) · Acta Physiologica · doi:10.1111/j.1748-1716.2007.01789.x · Cited by 10
Bloomgarden, Z. T. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1227 · Cited by 11
Therapeutic Strategies Exploiting DP IV Inhibition: Target disease: Type 2 Diabetes
Hoffmann, T., & Demuth, H. (2002) · Springer eBooks · doi:10.1007/978-1-4615-0619-5_10 · Cited by 9
Molecular basis of enhanced GLP-1 signaling mediated by GLP-1(9–36) in conjunction with LSN3318839
Li, J., Li, G., Mai, Y., Liu, X., Yang, D., Zhou, Q., & Wang, M. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.09.002 · Cited by 8
Gharib, S. A., Vemireddy, R., Castillo, J., Fountaine, B. S., Bammler, T. K., MacDonald, J. W., Hull, R. L., & Zraika, S. (2024) · Scientific Reports · doi:10.1038/s41598-024-76722-1 · Cited by 10
“Since GLP-1 is rapidly degraded by the proteases dipeptidyl peptidase-4 (DPP-4) and neprilysin 11–15 , it is thought that gut-derived GLP-1 mediates its insulinotropic action mainly via neuronal, rather than hormonal, pathways.”
BackgroundSaviano, A., Apta, B. H. R., Tull, S. P., Pezhman, L., Fatima, A., Sevım, M., Mete, A., Chimen, M., Schettino, A., Marigliano, N., et al. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107624 · Cited by 10
Microbial dipeptidyl peptidases of the S9B family as host-microbe isozymes
Aljumaah, M. R., Roach, J. M., Hu, Y., Gunstad, J., & Azcárate-Peril, M. A. (2025) · Science Advances · doi:10.1126/sciadv.ads5721 · Cited by 13
“Its physiological relevance in regulating incretin hormones was not established until the late 20th century ( 46 ), and it is now well-established that hDPP-4 is involved in many enzymatic and nonenzymatic functions ( 47 , 48 ).”
Gu, N., Adachi, T., Matsunaga, T., Takeda, J., Tsujimoto, G., Ishihara, A., Yasuda, K., & Tsuda, K. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.06.010 · Cited by 9
Evidence for neural contribution to islet effects of DPP-4 inhibition in mice
Ahlkvist, L., Omar, B. A., Pacini, G., & Åhrén, B. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.03.030 · Cited by 8
Food proteins in the regulation of blood glucose control
Luhovyy, B. L., & Kathirvel, P. (2022) · Advances in food and nutrition research · doi:10.1016/bs.afnr.2022.05.001 · Cited by 16
Glucagon-like peptide 1 and cardiac cell survival
Ravassa, S., Zudaire, A., & Díez, J. (2012) · Endocrinología y Nutrición (English Edition) · doi:10.1016/j.endoen.2012.11.004 · Cited by 11
The early history of GIP 1969–2000: From enterogastrone to major metabolic hormone
Marks, V. (2019) · Peptides · doi:10.1016/j.peptides.2019.170155 · Cited by 9
Andleeb, S., Nadia, A., Hussain, W., & Rasool, N. (2020) · International Journal of Clinical Microbiology and Biochemical Technology · doi:10.29328/journal.ijcmbt.1001008 · Cited by 8
“In the early 1990s, DPP4 was found to be involved in the inactivation of glucagon-like peptide 1 (GLP1) [7,8] and glucose-dependent insulinotropic polypeptide (GIP) [9].”
BackgroundWøjdemann, M., Riber, C., Bisgaard, T., Sternby, B., Larsen, S., Rehfeld, J. F., Holst, J. J., & Olsen, O. (1999) · Regulatory Peptides · doi:10.1016/s0167-0115(99)00011-7 · Cited by 11
Self-citationThe GetGoal clinical trial program of lixisenatide, a once-daily GLP-1 receptor agonist
Christensen, M., Knop, F. K., & Vilsbøll, T. (2011) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.11.30 · Cited by 7
Serum Levels of Incretin Hormones – GLP-1 and GIP in Patients with Type 1 Diabetes Mellitus
Stanchev, P. E., Orbetzova, M. M., Terzieva, D. D., Davcheva, D. M., Iliev, D. A., Petrov, S. V., Koleva, D. I., & Nonchev, B. (2019) · Folia Medica · doi:10.2478/folmed-2018-0056 · Cited by 7
Zhang, T., Liu, S., He, S., Shi, L., & Ma, R. (2025) · ChemBioChem · doi:10.1002/cbic.202400962 · Cited by 10
Kim, S.-J., Kwon, S. K., Kim, H., Kim, S. M., Bae, J., & Choi, J.-K. (2019) · BMC Nephrology · doi:10.1186/s12882-019-1243-z · Cited by 8
“However, half-life of native GLP-1 is within 2 min in vivo, which is due to degradation by the DPP-4 [18], it is hard to define rapid change after DPP-4 inhibition.”
BackgroundA new perspective of probe development for imaging pancreatic beta cell in vivo
Neo, C. W. Y., Ciaramicoli, L. M., Soetedjo, A. A. P., Teo, A. K. K., & Kang, N. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.01.009 · Cited by 8
Making Methods Rugged for Regulated Bioanalysis
Unger, S. E., Horvath, T. D., Tan, M. J. W., Zhou, J., Lloyd, T. L., McManus, K., & Wells, E. (2015) · Bioanalysis · doi:10.4155/bio.14.317 · Cited by 7
Takasaki, K., Takada, H., Nakajima, T., Ueno, K., Ushiki, J., & Higo, K. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.10.018 · Cited by 7
Eng, H. F., Sharma, R., McDonald, T. S., Landis, M. S., Stevens, B. D., & Kalgutkar, A. S. S. (2014) · Xenobiotica · doi:10.3109/00498254.2014.897011 · Cited by 9
“E-mail: amit.kalgutkar@pfizer.com (Hansen et al., 1999) to yield GLP-1(9-36)amide as a metabolite (Deacon et al., 1995a,1995b; Mentlein, 1999).”
BackgroundHaselmann, K. F., Nielsen, P. F., & Zubarev, R. A. (2005) · Journal of the American Society for Mass Spectrometry · doi:10.1016/j.jasms.2005.01.009 · Cited by 7
“Both degradation by dipeptidyl peptidase IV causing inactivity [ 6 ] and renal clearance [7] are severe, making once daily administration impossible.”
BackgroundUtilizing the GLP-1 signaling system to treat diabetes: Sorting through the pharmacologic approaches
D’Alessio, D. A., & Vahl, T. P. (2005) · Current Diabetes Reports · doi:10.1007/s11892-005-0092-2 · Cited by 7
“Metabolism of GLP-1 by DPP-IV results in a plasma half-life of 1 to 2 minutes [ 9 ], and because GLP-1(9-36)NH2 is inactive this process limits the overall effect of GLP-1 [10].”
BackgroundGrasset, E., Briand, F., Virgilio, N., Schön, C., Wilhelm, M. G., Cudennec, B., Ravallec, R., Aboubacar, H., Vleminckx, S., Prawitt, J., et al. (2024) · Food Science & Nutrition · doi:10.1002/fsn3.4538 · Cited by 9
“GLP-1 has a very short half-life in the systemic circulation of less than a minute (Deacon 2004; Deacon, Johnsen, and Holst 1995) due to its degradation by the dipeptidyl peptidase 4 (DPP-4), which also inactivates GIP (Seino, Fukushima, and Yabe 2010).”
Glucagon-like peptide-1(1–37) can enhance blood glucose homeostasis in mice
Zhao, L., Ye, H., Li, D., Lao, X., Li, J., Wang, Z., Xiao, L., Wu, Z., & Huang, J. (2012) · Regulatory Peptides · doi:10.1016/j.regpep.2012.06.010 · Cited by 7
Veedfald, S., Hansen, M., Christensen, L. W., Larsen, S. A. H., Hjøllund, K. R., Plamboeck, A., Hartmann, B., Deacon, C. F., & Holst, J. J. (2016) · Experimental Physiology · doi:10.1113/ep085692 · Cited by 6
“1999) and in a circulating form in plasma (Mentlein et al. 1993; Deacon et al. 1995).”
BackgroundSelf-citationA proopiomelanocortin‐derived peptide sequence enhances plasma stability of peptide drugs
Löw, K., Roulin, A., & Kunz, S. (2020) · FEBS Letters · doi:10.1002/1873-3468.13855 · Cited by 8
Treatment of Type 2 diabetes mellitus based on glucagon-like peptide-1
Holst, J. J. (1999) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.8.9.1409 · Cited by 6
“It has become apparent that GLP-1 is metabolised by several mechanisms, the earliest and the most extensive being an N-terminal truncation by two amino acid residues catalysed by the ubiquitous enzyme, dipeptidyl peptidase IV (DPP-IV) [30].”
BackgroundSelf-citationVildagliptin Does Not Affect C‐Peptide Clearance in Patients With Type 2 Diabetes
He, Y., Horowitz, A., Watson, C. E., Foley, J. E., Sallas, W. M., & Ligueros‐Saylan, M. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006295061 · Cited by 6
Glucagon like peptide-1: A new therapeutic target for diabetes mellitus
Patel, S., Goyal, R., Anand, I., Shah, J., Patel, H., & Patel, C. (2006) · Indian Journal of Pharmacology · doi:10.4103/0253-7613.27018 · Cited by 7
“This enzyme cleaves GLP-1 at the alanine residue at position 2,([7]) which not only inactivates GLP-1, but also might turn it into an antagonist at the GLP-1 receptor.”
BackgroundMeng, Y., Wang, Y., Fu, W., Zhang, M., Huang, J., Wu, H., & Sun, L. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02575-6 · Cited by 7
“Dipeptidyl peptidase-4 inhibitors (DPP-4i) are glucose-lowing agents by inhibiting dipeptidyl peptidase-4 (DPP-4) which is the catabolic enzyme of GLP-1 (Deacon et al. 1995).”
BackgroundCarpio, L. E., Olivares, M., Benítez‐Páez, A., Serrano‐Candelas, E., Barigye, S. J., Sanz, Y., & Gozalbes, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115744 · Cited by 5
“…individuals and those with T2DM demonstrated that the metabolite resulting from DPP4 cleavage is the primary circulating form of GLP-1-like immunoreactivity [27] and that this metabolite is rapidly formed following exogenous administration of GLP-1 in both healthy subjects and those with T2DM [28].”
BackgroundFeitosa, S. G. D., Lins, I. M. S., Maciel, L. G., & dos Anjos, J. V. (2024) · Journal of Heterocyclic Chemistry · doi:10.1002/jhet.4811 · Cited by 6
Deng, W., Qiu, S., Yang, G., & Chen, B. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s81088 · Cited by 6
Tanaka‐Amino, K., Matsumoto, K., Hatakeyama, Y., Takakura, S., & Mutoh, S. (2009) · Acta Diabetologica · doi:10.1007/s00592-009-0096-5 · Cited by 5
“Chronic infusion of GLP-1 for the treatment of type 2 diabetes resulted in improved blood glucose and hemoglobin A1c (HbA1c )[ 5]. However, the action of GLP-1 has a very short half-life of about 1 min due to its degradation by dipeptidyl peptidase 4 (DPP4, EC 3.4.14.5) [ 6 ].”
BackgroundInfluentialInvestigation of the Feasibility of an Amide-based Prodrug Under Physiological Conditions
De, A., & DiMarchi, R. D. (2008) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-008-9152-1 · Cited by 5
Effect of glycosylation on biodistribution of radiolabeled glucagon-like peptide 1
Watanabe, A., Nishijima, K., Zhao, S., Tanaka, Y., Itoh, T., Takemoto, H., Tamaki, N., & Kuge, Y. (2011) · Annals of Nuclear Medicine · doi:10.1007/s12149-011-0558-z · Cited by 5
Setji, T. L., & Feinglos, M. N. (2013) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.13.2 · Cited by 5
Freyse, E., Berg, S., Kohnert, K., Heinke, P., & Salzsieder, E. (2011) · Biological Chemistry · doi:10.1515/bc.2011.027 · Cited by 6
The safety of albiglutide for the treatment of type 2 diabetes
Rendell, M. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1351538 · Cited by 6
GLP-1(28-36)amide, the Glucagon-like peptide-1 metabolite: friend, foe, or pharmacological folly?
Whitehead, J. P., Taing, M., & Rose, F. J. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s35723 · Cited by 11
“in the circulation, GLP-1(7-36)amide has a half-life of less than 2 minutes, being subject to rapid cleavage between positions 8 and 9 by the ubiquitously expressed enzyme diaminopeptidyl peptidase IV (DPP-4), which gives rise to GLP-1(9-36)amide.”
InfluentialGLP‐1 C‐terminal structures affect its blood glucose lowering‐function
Li, Y., Shi, C., Lv, Q.-J., Zhang, H., Biehu, L., Bian, G., Huang, Q., Zhang, W., Xue, X., Ren, X., et al. (2008) · Journal of Peptide Science · doi:10.1002/psc.997 · Cited by 5
“This short half-life of GLP-1 is attributable to the degradation of the amino acid at the 8th position by dipeptidyl peptidase IV (DPP-IV) as well as the rapid clearance of GLP-1 in vivo [9,10].”
BackgroundDoggrell, S. A. (2007) · Reviews on Recent Clinical Trials · doi:10.2174/157488707779318053 · Cited by 5
“GLP-1 is metabolised by dipeptidyl peptidase IV with an apparent half-life of 60-80 seconds, with the metabolite acting as an antagonist at the GLP-1 receptor [6,7].”
BackgroundApplication of nanomaterials for imaging pancreatic islets
Kim, M. J., & Lee, D. Y. (2016) · Macromolecular Research · doi:10.1007/s13233-016-4034-4 · Cited by 5
Nauck, M. A., Schmidt, W. E., & Meier, J. J. (2007) · Springer eBooks · doi:10.1007/978-0-387-69737-6_12 · Cited by 5
“DPP-4 nonspecifically cleaves peptides displaying a proline or alanine residue in the second amino-terminal position, thereby making a number of gastrointestinal hormones, including GIP [38,138,141], GLP-1 [37,38,138,142], GLP-2, PACAP, Neuropeptide Y, and Peptide YY substrates to DPP-4 degradation [39].”
BackgroundPhysiology and Pathophysiology of GLP-1
Göke, B., Göke, R., Fehmann, H. C., & Bode, H. (1996) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-61150-6_17 · Cited by 6
Recent and Future Drugs for the Treatment of Obesity
Gaal, L. F. V., Mertens, I. L., & Leeuw, I. H. D. (2001) · Wiley eBooks · doi:10.1002/0470846739.ch31 · Cited by 7
“However, GLP-1 is metabolized very quickly by the dipeptidyl-peptidase IV (DPP-IV) enzyme (122), making it difficult to turn GLP-1 into a clinical useful therapeutic agent.”
BackgroundIntestinal Proglucagon-Derived Peptides
Brubaker, P. L., & Drucker, D. J. (1999) · Humana Press eBooks · doi:10.1007/978-1-59259-695-9_20 · Cited by 7
A Survey and Guide to the Development of Fatty Acid‐derivatized Peptide Therapeutics
Jacobsen, M. T., Poulsen, C., Kopp, K. L., Olsen, J., & Cox, N. (2025) · Wiley eBooks · doi:10.1002/9781119824701.ch07 · Cited by 5
Wang, Z., Lin, S., Dong, X., Cao, J., Zhao, R., Wu, L., & Shen, S. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03270 · Cited by 5
Targeting cardiometabolic risk in type 1 diabetes through incretin physiology
Frampton, R., HOCKING, S. L., SNAITH, J. R., & Greenfield, J. R. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.06.004 · Cited by 4
Bioequivalence study of different brands of vildagliptin in healthy human subjects
Sharma, M., & Agrawal, S. S. (2021) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-021-00308-1 · Cited by 4
“GLP-1, which is in circulation, degraded rapidly, and its degradation is inhibited by DPP-4 [3, 6].”
BackgroundInfluentialGnoth, K., Bär, J. W., Rosche, F., Rahfeld, J., & Demuth, H. (2024) · PLoS ONE · doi:10.1371/journal.pone.0289239 · Cited by 5
Trung, V. N., Yamamoto, H., Yamaguchi, T., Murata, S., Aimi, Y., Kuwahara, A., & Tani, T. (2013) · Peptides · doi:10.1016/j.peptides.2013.12.003 · Cited by 4
Sitagliptin: an oral agent for glucose control
Bardsley, J. K., & Ratner, R. E. (2008) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.3.6.691 · Cited by 4
Mulherin, A. J., Oh, A., Kim, H., Grieco, A., Lauffer, L., & Brubaker, P. (2011) · Obesity and metabolism · doi:10.14341/2071-8713-5305 · Cited by 4
Incretins and Regulation of Insulin Secretion
Nauck, M. A., & Meier, J. J. (2008) · Springer eBooks · doi:10.1007/978-4-431-75452-7_17 · Cited by 4
Potential Role of GLP-1 Based Therapeutics in Coronary Artery Disease
Xiong, Q., Wang, J., Huang, K., Li, W., & Zhang, L. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2811315 · Cited by 4
“Yet, it undergoes rapid conversion into GLP-1 (9-36) [11].”
BackgroundGLP 1/2, Enteroglucagon, Glicentin, and Oxyntomodulin
Holst, J. J., Deacon, C. F., & Pedersen, J. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-385095-9.00168-8 · Cited by 6
Self-citationIncretinas: Un nuevo paradigma en el tratamiento de la diabetes mellitus tipo 2
Blumenfeld, O. S. (2009) · Revista de Endocrinología y Nutrición · Cited by 8
Treatment Strategies for Type 2 Diabetes Based on Incretin Action
Gallwitz, B., & Nauck, M. A. (2007) · CRC Press eBooks · doi:10.3109/9780849379581-13 · Cited by 5
A surface plasmon resonance assay for characterisation and epitope mapping of anti‐GLP‐1 antibodies
Thomsen, L., & Gurevich, L. (2018) · Journal of Molecular Recognition · doi:10.1002/jmr.2711 · Cited by 4
“Accordingly, early immunoassays, radioimmunoassays and sandwich enzyme‐linked immunosorbent assays (ELISA), displayed significant discrepancies in measurements caused by differences in cross‐reactivity of the antibodies.(29,30) Collectively, well‐characterised antibodies with high specificity and affinity are crucial…”
BackgroundGastrointestinal Peptide Hormones Regulating Energy and Glucose Homeostasis
Drucker, D. J. (2006) · Elsevier eBooks · doi:10.1016/b978-012088394-3/50009-x · Cited by 6
Glucagon and Glucagon‐like Peptide Production and Degradation
Kieffer, T. J., Hussain, M. A., & Habener, J. F. (2001) · Comprehensive physiology · doi:10.1002/cphy.cp070208 · Cited by 6
Glucagon-Like Peptide-1 and Diabetes 2012
Monami, M., Pasquale, G. D., Rowzee, A. M., Rotella, C. M., & Mannucci, E. (2012) · Experimental Diabetes Research · doi:10.1155/2012/768760 · Cited by 5
Exenatide: incretin therapy for patients with Type 2 diabetes mellitus
Tahrani, A. A., Piya, M. K., & Barnett, A. H. (2008) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.3.6.671 · Cited by 5
A Critical Account of Synthetic Approaches toward Vildagliptin, an Antidiabetic Drug
Rathod, V. D., Saini, P., Kaur, R., Marimganti, S., & Ranbhan, K. J. (2023) · Organic Process Research & Development · doi:10.1021/acs.oprd.3c00048 · Cited by 3
Sridhar, A., Khan, D., Babu, G., Irwin, N., Gault, V. A., Flatt, P. R., & Moffett, R. C. (2024) · Peptides · doi:10.1016/j.peptides.2024.171254 · Cited by 6
“Hence, around 70 % of GIP in circulation exists as GIP(3 (cid:0) 42) [13] and 60 % of GLP-1 as GLP-1(9 (cid:0) 36) [14], as measured approximately 1 hour after a mixed meal in humans.”
BackgroundHolst, J. J. (2024) · The Journal of Physiology · doi:10.1113/jp287461 · Cited by 5
Self-citationGlucagon-like Peptide 1 and Type 2 Diabetes: Targets and New Therapies
Sheikhpour, R. (2012) · Indian Journal of Science and Technology · doi:10.17485/ijst/2012/v5i6/30482 · Cited by 3
“Mentlein R, Gallwitz B and Schmidt WE (1993) Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum.”
BackgroundBurcelin, R., & Bertolini, M. (2013) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(13)70590-x · Cited by 6
López-Jaramillo, P. A., Velandia, C., Castillo, G., Sánchez, T. E. A., & Álvarez, J. (2013) · Revista Colombiana de Cardiología · doi:10.1016/s0120-5633(13)70072-x · Cited by 5
“Esta rápida inactivación de GLP-1 fue demostrada claramente por estudios en humanos donde se reportó que después de treinta minutos de la aplicación subcutánea, la forma inactiva de GLP-1 (9-36) amida representa un 78% del total del GLP-1 inmmunorreactivo (61); sin embargo, la forma GLP-1 amida (9-36) puede disminuir…”
BackgroundLin, Y.-H., & Huang, H. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s220180 · Cited by 4
“The study suggested that high baseline HbA1c level, low BMI, short T2D duration, and fewer kinds of OADs are the predictors of the efficacy of DPP-4 inhibitors in Taiwanese patients with T2D.”
MethodInfluentialCantini, G., Trabucco, M., Dicembrini, I., Mannucci, E., & Luconi, M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813814-4.00016-x · Cited by 3
Ji, L., Lu, J., Gao, L., Ying, C., Sun, J., Han, J., Zhao, W., Gao, Y., Wang, K., Zheng, X., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15261 · Cited by 4
Sharma, M. C., Jain, S. K., & Sharma, R. (2017) · In Silico Pharmacology · doi:10.1007/s40203-017-0032-2 · Cited by 3
“Thus inhibition of the DPP-4 has appeared as a major target of diabetes research (Holst 1999, 2005; Hui et al. 2005; Deacon et al. 1995).”
Management of type 2 diabetes: the GLP‐1 pathway
Tahrani, A. A., Piya, M. K., & Barnett, A. H. (2008) · Future Prescriber · doi:10.1002/fps.39 · Cited by 3
Incretin Based Therapies in Type 2 Diabetes Mellitus
Göksu, U. A., & Ünal, A. (2017) · Kafkas Journal of Medical Sciences · doi:10.5505/kjms.2017.94830 · Cited by 6
Ramos, D. C., Almeda‐Valdés, P., Meza-Arana, C. E., Brito-Córdova, G. X., Ruiz-Gómez, D. G., Razo, C., & Gomez-Perez, F. J. (2019) · Gaceta Médica de México · doi:10.24875/gmm.m17000007 · Cited by 4
Gliptin Therapies for Inhibiting Dipeptidyl Peptidase-4 in Type 2 Diabetes
Green, B. D., Bailey, C. J., & Flatt, P. R. (2010) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2010.06.02.19 · Cited by 4
“Mentlein R, Gallwitz B, Schmidt WE, Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum, Eur J Biochem, 1993;214:829–35.”
BackgroundInfluentialPotential of GLP-1 in Diabetes Management
Holst, J. J., Nauck, M. A., Deacon, C. F., & Ørskov, C. (1996) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-61150-6_18 · Cited by 5
Self-citationWilliams, J. A. (2014) · doi:10.3998/panc.2014.7 · Cited by 4
Carpio, L. E., Olivares, M., Ortega-Vallbona, R., Serrano‐Candelas, E., Sanz, Y., & Gozalbes, R. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125579 · Cited by 2
Frost, K., Urbanowski, A. M., Neag, G., Lewis, J. W., Northall, E., Kemble, S., Powell, E., Croft, A. P., Iqbal, A. J., Rainger, G. E., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118489 · Cited by 3
Arterburn, D. E., Curtis, L. H., Toh, S., Bradley, M. C., D’Alessio, D., Duchovny, N., Hines, D. W., Narain, K. D. C., Parekh, A., Skinner, A., et al. (2026) · Annals of Internal Medicine · doi:10.7326/annals-25-05468 · Cited by 3
Structural Biology and Molecular Modeling in the Design of Novel DPP-4 Inhibitors
Scapin, G. (2009) · NATO science for peace and security series. A, Chemistry and biology · doi:10.1007/978-90-481-2339-1_10 · Cited by 2
Liraglutid - vozmozhnosti kompleksnogo terapevticheskogo podkhoda v terapii SD 2 tipa
Shestakova, M. V. (2009) · Diabetes Mellitus · doi:10.14341/2072-0351-5807 · Cited by 4
Synthetic protease-activated class B GPCRs
Willard, F. S., Meredith, T. D., Showalter, A. D., Ma, W., Ho, J. D., Sauder, J. M., & Sloop, K. W. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.07.021 · Cited by 2
Novel DPP-IV-resistant Analogs of GLP-1: The N-terminal Extension of GLP-1 by a Single Amino Acid
Oh, J.-Y., Lee, C., Jang, S.-H., Yoo, S.-B., & Chung, H.-S. (2009) · Bulletin of the Korean Chemical Society · doi:10.5012/bkcs.2009.30.10.2471 · Cited by 2
Begley, J., Bowes, A., Hart, T., Zouwail, S., & Kerr, D. E. (2013) · journal of Diabetes Research and Clinical Metabolism · doi:10.7243/2050-0866-2-10 · Cited by 2
Kim, J. W., Kim, K., Ahn, Y.-J., Jeong, H.-J., Jeong, H.-Y., Ryu, S.-H., Lee, S., Lee, C., Chung, H.-S., & Jang, S. (2010) · BMB Reports · doi:10.5483/bmbrep.2010.43.2.146 · Cited by 2
“Kim et al. showed that Fc fusion to GLP-1 attenuated degradation by DPP-IV in vitro (9).”
BackgroundInfluentialHribal, M. L., & Sesti, G. (2011) · Clinical Investigation · doi:10.4155/cli.10.26 · Cited by 2
Coming of Age for the Incretins
Holst, J. J., & Deacon, C. F. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-572-5_14 · Cited by 2
Self-citationSignificance of Organ Crosstalk in Insulin Resistance and Type 2 Diabetes
Bhatt, S., & Kulkarni, R. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-415784-2.00017-8 · Cited by 3
GÓRSKA, A., & Arciszewski, M. B. (2020) · Medycyna Weterynaryjna · doi:10.21521/mw.6374 · Cited by 3
Non‐Insulin Parenteral Therapies
Holst, J. J., Madsbad, S., & Schmitz, O. (2010) · Wiley eBooks · doi:10.1002/9781444324808.ch30 · Cited by 4
Self-citationCornell, S. A. (2006) · Journal of Pharmacy Technology · doi:10.1177/875512250602200207 · Cited by 2
Sitagliptin: results from clinical practice
Maffioli, P., & Derosa, G. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.835716 · Cited by 2
Metadata
- Authors
- Deacon, C. F., Johnsen, A. H., & Holst, J. J.
- Affiliations
- University of Copenhagen (DK)
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1995-03
- Volume
- 80
- Issue
- 3
- Pages
- 952-957
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2068183831
- Cited by
- 792
- References
- 28
- Citations by year
- 2026: 5 · 2025: 14 · 2024: 24 · 2023: 10 · 2022: 14 · 2021: 24 · 2020: 18 · 2019: 34 · 2018: 25 · 2017: 37 · 2016: 41 · 2015: 22 · 2014: 27 · 2013: 40 · 2012: 42
- FWCI
- 9.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Peptidase Inhibition and Analysis
- Keywords
- glucagon-like peptide-1, dipeptidyl peptidase IV, human plasma, peptide metabolism, endogenous metabolites
- MeSH terms
- Chromatography, High Pressure Liquid, Female, Glucagon, Humans, Male, Peptide Fragments, Protein Precursors, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.